• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Arch Microbiol . The protective effect and mechanism of rhIFN-α1b on lung injury in mice infected with H1N1 influenza A virus

tetano

Editor, Senior Moderator
Arch Microbiol


. 2025 Nov 12;208(1):8.
doi: 10.1007/s00203-025-04568-w. The protective effect and mechanism of rhIFN-α1b on lung injury in mice infected with H1N1 influenza A virus

Yao Zhang[SUP] 1 [/SUP], Chen Xu[SUP] 2 [/SUP], Xin Sun[SUP] 1 [/SUP], Jinyi Liu[SUP] 3 [/SUP], Guocheng Zhang[SUP] 4 [/SUP]



Affiliations
Abstract

Recombinant human interferon-α1b (rhIFN-α1b) has shown proven antiviral and immunomodulatory effects in multiple viral infections. This study was designed to explore the protective effect and mechanism of rhIFN-α1b on lung injury in mice infected with influenza A virus (H1N1). The lung-adapted strain of influenza A virus NYMCX-179 A was inoculated into mice via intranasal infection, followed by administration of rhIFN-α1b. Mouse lung tissues exhibited significant inflammatory damage, enhanced HA expression, and distinct distribution of viral particles (observed by TEM). Administration of rhIFN-α1b or oseltamivir reduced mouse mortality, alleviated lung tissue inflammation, downregulated HA expression, decreased H1 mRNA levels, and attenuated the secretion of inflammatory cytokines. Moreover, the in vivo protective effect of rhIFN-α1b administered via nebulization was stronger than that of intramuscular injection. In vitro, rhIFN-α1b reduced inflammatory cytokine secretion, diminished HA protein and H1 mRNA levels, and inhibited apoptosis in H1N1 virus-infected MDCK cells. Mechanistically, rhIFN-α1b increased the protein levels of phosphorylated JAK2 (p-JAK2) and phosphorylated STAT3 (p-STAT3) in both H1N1 virus-infected MDCK cells and lung tissues from mice with lung injury. Additionally, treatment with AG490-a JAK/STAT signaling inhibitor-reversed the effects of rhIFN-α1b on HA expression, inflammatory cytokine secretion, and cell apoptosis in H1N1 virus-infected MDCK cells. These findings demonstrated that rhIFN-α1b ameliorates lung tissue damage in H influenza A virus (H1N1)-infected mice, with the protective effect of nebulized rhIFN-α1b being stronger than that of intramuscularly administered rhIFN-α1b. Furthermore, the protective effect of rhIFN-α1b is associated with the activation of the JAK/STAT signaling pathway.

Keywords: Influenza a virus; JAK/STAT signaling; Pneumonia; RhIFN-α1b.

 
Back
Top